1. Home
  2. FIG vs DVA Comparison

FIG vs DVA Comparison

Compare FIG & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FIG

Figma Inc.

HOLD

Current Price

$19.11

Market Cap

10.6B

Sector

Technology

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$198.63

Market Cap

9.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIG
DVA
Founded
2012
1994
Country
United States
United States
Employees
1886
N/A
Industry
Computer Software: Prepackaged Software
Misc Health and Biotechnology Services
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6B
9.9B
IPO Year
N/A
2002

Fundamental Metrics

Financial Performance
Metric
FIG
DVA
Price
$19.11
$198.63
Analyst Decision
Hold
Hold
Analyst Count
13
4
Target Price
$50.50
$156.75
AVG Volume (30 Days)
14.6M
824.0K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.87
Revenue
N/A
$13,643,069,000.00
Revenue This Year
$31.18
$3.85
Revenue Next Year
$20.22
$3.07
P/E Ratio
N/A
$69.74
Revenue Growth
N/A
6.46
52 Week Low
$16.60
$101.00
52 Week High
$114.29
$202.69

Technical Indicators

Market Signals
Indicator
FIG
DVA
Relative Strength Index (RSI) 47.01 81.52
Support Level $17.13 $145.58
Resistance Level $21.45 N/A
Average True Range (ATR) 1.06 7.01
MACD 0.36 4.94
Stochastic Oscillator 54.39 93.02

Price Performance

Historical Comparison
FIG
DVA

About FIG Figma Inc.

Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Share on Social Networks: